Objective To study the relationship between EML4‐ALK fusion gene mutations and clinical characteristics and survival in NSCLC . Methods A total of 82 patients’ clinical data were col‐lected ,including the patient’s age ,sex ,smoking history ,histological type ,tumor metastasis ,clinical stage or postoperative staging and EGFR mutations . The survival data were collected by chart study and telephone interview . Results Of all 82 patients ,9 were detected positive for EML4‐ALK fusion gene mutations . Between the mutation positive group and the negative group there was no significant differ‐ence in gender ,tumor histological type ,tumor metastasis status ,and pathologic stage(P>0 .05) . There was a statistically significant difference in smoking history and EGFR mutations (P<0 .05) . The median of survival time was 23 months for the gene mutation negative group and 21 months for the gene mutation positive group(P> 0 .05) . Conclusion EML4‐ALK fusion gene mutation is more inclined to occur in women ,non‐smokers ,adenocarcinoma ,and patients without EGFR gene mutation . The meanwhile of EM L4‐ALK fusion gene mutation can not yet be used as an independent factor in the assessment of non‐small cell lung cancer prognosis .%目的：探讨非小细胞肺癌（NSCLC）中棘皮动物微管蛋白4‐间变性淋巴瘤激酶（EML4‐ALK）融合基因突变情况与临床特征、生存时间的关系。方法回顾性分析82例NSCLC患者的临床资料，包括患者的年龄、性别、吸烟史、病理类型、肿瘤转移、临床分期或术后分期及表皮生长因子受体（EGFR）突变情况等，并通过阅览病例、电话随访等方式随访其生存情况。结果82例中，检测出EML4‐ALK融合基因突变9例为突变阳性组，总突变率为10．98％，余为突变阴性组。2组在性别、肿瘤病理类型、肿瘤转移、病理分期等方面比较，差别无统计学意义（P＞0．05）；2组在吸烟史、EGFR基因突变情况的比较，差别有统计学意义（P＜0．05）。突变阳性组与突变阴性组的中位生存期分别为21月（95％ C I ，18～24月）和23月（95％ C I ，22～24月），差别无统计学意义（ P＜0．05）。结论 EML4‐ALK融合基因突变多倾向于女性、不吸烟、腺癌与EGFR基因无突变的患者。EML4‐ALK融合基因突变尚不能作为评估NSCLC近期预后的独立因素。
展开▼
